Original Research Article
Year: 2021 | Month: July | Volume: 8 | Issue: 7 | Pages: 402-409
DOI: https://doi.org/10.52403/ijrr.20210758
Assessment of Aberrant Promoter Hypermethylation of RASSF1a and P16 in Endometrial Carcinoma
Nagaratna Shivanandappa1, Shalini N Swamy2, Sandeep Kumar S3, Suma Sheshadri4, Venkateshaiah Reddihalli Pallavi5, Ramesh Gawari6
1Research Scholar, Department of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
2Research Scholar, Department of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
3Senior Research Fellow, Department of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
4Associate Professor, Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
5Professor, Department of Gynaecology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
6Professor, Department of Biochemistry, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
Corresponding Author: Ramesh Gawari
ABSTRACT
Endometrial carcinoma is one of the most common gynecological malignancies known to affect around 142000 women worldwide. Aberrant promoter hypermethylation of tumor suppressor genes is a common epigenetic alteration reported in cancers. In the present study we report the aberrant promoter hypermethylation of RASSF1a and p16 in 78 endometrial cancer patients.
Methods: Endometrial carcinoma samples were collected after pathological examination and DNA was extracted. The DNA was subjected to sodium bisulfite modification and then used to perform methylation specific PCR. The PCR was performed using a two step procedure of nested and methylation specific PCR. The PCR product was visualized using agarose gel electrophoresis. The results obtained were correlated with various clinicopathological parameters. Chi square test was used for statistical analysis and a p-value of <0.05 was considered statistically significant.
Result: 60 of the 78 (76.92%) samples showed methylation for RASSF1a gene. 28 of the 78 (35.8%) samples showed methylation for p16 gene. A higher methylation frequency was observed for RASSF1a in the endometrioid and poorly differentiated histological subtypes and stage I and II of the disease.
Conclusion: Aberrant promoter hypermethylation of RASSF1a and p16 is known to play an important role in endometrial cancer initiation and progression. The methylation patterns can be used as an important molecular marker for early diagnosis and prognosis of endometrial cancer.
Keywords: Epigenetic alterations, DNA Hypermethylation, Endometrial cancer, RASSF1a, p16, Methylation-specific PCR.
[PDF Full Text]